Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (Nasdaq: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline.

If you purchased shares of Keryx during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made false and misleading statements and/or failed to disclose that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLPJoon M. Khang, Esq.Telephone: 949-419-3834Facsimile: 949-225-4474joon@khanglaw.com

Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.